Investors who purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023, and December 26, 2025, are being encouraged by the law firm of Rosen to inquire about a securities class action lawsuit. The firm is investigating potential violations of federal securities laws on behalf of shareholders during this period, often referred to as the “Class Period.” This action centers on allegations of misstatements and omissions related to the company’s drug development, specifically setrusumab.
The lawsuit alleges that Ultragenyx made false and/or misleading statements throughout the Class Period, failing to disclose critical information regarding setrusumab’s efficacy and potential risks. Specifically, the complaint claims the company created a misleadingly positive impression about the reliability of data pertaining to the drug’s effects on patients with Osteogenesis Imperfecta, while downplaying the likelihood of unfavorable results in the Phase III Orbit study. These alleged misrepresentations potentially impacted investor confidence and the company’s stock price.
Rosen Law Firm is actively investigating these claims and seeking to determine the full extent of the alleged wrongdoing. Investors who experienced losses as a result of investing in Ultragenyx during the specified timeframe may have legal recourse. The firm specializes in representing investors in securities class action lawsuits and is dedicated to protecting their rights.
Details of the Lawsuit
The lawsuit, filed in the United States District Court for the Northern District of California, is captioned Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 (N.D. Cal.). The core allegation revolves around the alleged misrepresentation of data related to setrusumab, a drug intended to treat Osteogenesis Imperfecta, a genetic disorder characterized by fragile bones. The complaint suggests that Ultragenyx presented an overly optimistic view of the drug’s potential, while minimizing the risks associated with its clinical trials.
According to the legal filings, the defendants allegedly failed to disclose that patients participating in the Phase III Orbit study were unlikely to achieve a statistically significant reduction in annualized fracture rate (AFR). This alleged omission is central to the claim that investors were misled about the true prospects of setrusumab and the company’s overall financial health. The lawsuit contends that this lack of transparency ultimately harmed investors when the true data came to light.
Key Dates and Deadlines
A critical deadline for investors seeking to participate in the lawsuit as a lead plaintiff is approaching. Investors must file for lead plaintiff status by April 6, 2026. The lead plaintiff is the investor who represents the interests of all class members throughout the litigation process. This role carries significant responsibility, including actively participating in the direction of the lawsuit.
Several firms are involved in representing investors in this case. In addition to Rosen Law Firm, Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is also actively involved, having initially filed the lawsuit. The Gross Law Firm is also encouraging investors to contact them regarding potential lead plaintiff appointment, as reported on Pharmiweb. Investors are encouraged to contact any of these firms to discuss their legal options.
What Investors Should Do
Investors who purchased Ultragenyx Pharmaceutical Inc. (RARE) stock between August 3, 2023, and December 26, 2025, and experienced losses are urged to contact the firms mentioned above to explore their legal rights. There is no cost to investors for a consultation. The firms will evaluate individual cases to determine eligibility for participation in the class action lawsuit.
The outcome of this lawsuit could have significant implications for Ultragenyx Pharmaceutical Inc. And its shareholders. A successful outcome for the plaintiffs could result in financial recovery for investors who suffered losses due to the alleged misrepresentations. The case is being closely watched by the investment community as a potential example of the importance of transparency and accurate reporting in the pharmaceutical industry.
The next key date is the April 6, 2026 deadline for investors to seek lead plaintiff status. Following this, the court will likely address motions and begin the discovery phase, where evidence is gathered and analyzed. The timeline for a final resolution of the case remains uncertain, but investors are encouraged to stay informed about developments.
Disclaimer: This article is for informational purposes only and does not constitute legal or financial advice. Investors should consult with a qualified attorney to discuss their specific circumstances.
Please share this article with anyone who may be affected by this situation and depart your thoughts in the comments below.
